It has been reported that in patients with BCLC stage 0 and stage A HCC, the positive rate of GPC3 (76.43%, 120/157) was significantly higher than that of AFP (64.33%, 101/157; p = 0.019), while no difference was detected in the positive rates between the two groups in patients with stage B and stage C HCC, indicating that serum GPC3 is superior to AFP as a sensitive marker for early HCC [58]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.